Reprocell grows cell and tissue-based services in Scotland

By Flora Southey

- Last updated on GMT


Related tags Cell

Human tissue-focused products and services firm Reprocell Europe has opened headquarters in Glasgow, Scotland, which it says will boost business and create jobs.

CEO David Bunton told us the site, which is the first headquarters of Reprocell Europe – an offshoot of Japan-based Reprocell – will focus on cell and tissue therapies. 

“The Centre for Predictive Drug Discovery will be Reprocell’s main centre for the provision of human cell and tissue-based drug discovery services, with clients worldwide,”​ he said.

“We are aiming to grow our business by offering the most relevant human-based preclinical models in stem cells, 3D tissues and human fresh tissues,” ​he added.

Bunton said the decision to establish headquarters in Scotland came from Reprocell’s acquisition of UK firms Biopta and Reinnervate, which were brought together to form Reprocell Europe in 2016.

“Scotland has a leading reputation in pharmacology and was the base for Biopta Ltd, which Reprocell acquired in Dec 2015,”​ Bunton explained.

“The new Centre for Predictive Drug Discovery builds on not only the Biopta human fresh tissue services but also offers stem cell reprogramming and 3D tissue assay services,”​ he added.

New jobs

Bunton said the Centre will grow its Glasgow-based workforce and expand operations to focus on the launch on new services.

“We plan to create 15 new jobs (three already in post) over the next two years, boosting our RNA-based stem cell reprogramming services,” ​he told us.

Reprocell Europe offers stem cell, human tissue and 3D cell culture-based products and services to Europe, the Middle East and Africa.

Related topics Clinical Development Preclinical

Related news

Related products

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Content provided by Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

Related suppliers

Follow us


View more